CSL Vifor Reaffirms Its Commitment to the Vasculitis Community
Amid difficult news, a partner that stays present.
On the same day that the EMA published its recommendation to revoke the marketing authorisation for Tavneos (avacopan), CSL Vifor — the company responsible for commercialising Tavneos outside the United States — issued a public statement to the ANCA-associated vasculitis community.
In their statement, CSL Vifor acknowledged the impact this decision has on patients, confirmed that patient care remains their highest priority, and pledged continued support for patients and healthcare providers through the transition. They have indicated that patients currently receiving Tavneos should speak with their treating physician as the most important next step.
Vasculitis International appreciates this commitment. Today’s news is hard for patients and for the community as a whole. The vasculitis community deserves partners who stay present — especially when the news is hard. We will continue to work with all stakeholders, including industry partners, to ensure that patients are supported and that the case for research into better treatment options remains firmly on the agenda.
Practical information for patients currently on Tavneos
If you are currently being treated with Tavneos, the most important step is to contact your treating physician to discuss next steps. Do not stop treatment without medical guidance, and ensure that your liver function is being monitored according to the schedule specified in the EMA’s guidance (see our main article on the EMA decision for full details).
CSL Vifor’s Medical Information team can also be reached directly at: medinfo@viforpharma.com
Read the full CSL Vifor statement
About Vasculitis International
Vasculitis International (VI) is a European umbrella foundation supporting Vasculitis Patient Advocacy Groups (VPAGs) across 14+ European countries. More information: www.vasculitisint.com